Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year.
As of March 31, 2024, the Company had $95.5 million in cash and U.S treasury bills.
Posted In: BLTE